Based on the findings of the current study and the results of other studies, we propose the following mechanism: effective bevacizumab treatment occurs when the anti-VEGF agent binds to VEGFA, inhibiting blood vessel formation in the tumor microenvironment (TME) and increasing hypoxia due to reduced vessel density [1]. This evidence concerns the gene VEGFA and neoplasm.